2008 Index

December 2008
Clinical Trials Administrator;Dec2008 Supplement, following p144
A subject index for the December 2, 2008 issue of "Clinical Trials Administrator" is presented.


Related Articles

  • CLINICAL TRIALS ADMINISTRATOR 2011 Index.  // Clinical Trials Administrator;Dec2011 Supplement, Vol. 9, p1 

    No abstract available.

  • Clinical Trials ADMINISTRATOR. 2010 Index.  // Clinical Trials Administrator;Dec2010 Supplement, Vol. 8, p1 

    A subject index for the back issues of the journal "Clinical Trials Administrator" is presented.

  • Prognostic Indices for Budd–Chiari Syndrome: Valid for Clinical Studies but Insufficient for Individual Management. Rautou, Pierre-Emmanuel; Moucari, Rami; Escolano, Sylvie; Cazals-Hatem, Dominique; Denié, Cécile; Chagneau-Derrode, Carine; Charpignon, Claire; de Lédinghen, Victor; Grenouillet-Delacre, Marieke; Habersetzer, François; Nousbaum, Jean-Baptiste; Denninger, Marie-Hélène; Valla, Dominique C.; Plessier, Aurélie // American Journal of Gastroenterology;May2009, Vol. 104 Issue 5, p1140 

    OBJECTIVES:Several prognostic indices (PIs) have been proposed for Budd–Chiari syndrome (BCS). However, patient characteristics, causal factors, and treatment outcomes have changed since these indices have been elaborated. Validation in a recent patient population and comparison of...

  • Does Glycemic Control Offer Similar Benefits Among Patients With Diabetes in Different Regions of the World? WOODWARD, MARK; PATEL, ANUSHKA; ZOUNGAS, SOPHIA; LISHENG LIU; CHANGYU PAN; POULTER, NEIL; JANUSZEWICZ, ANDRZEJ; TANDON, NIKHIL; JOSHI, PRASHANT; HELLER, SIMON; NEAL, BRUCE; CHALMERS, JOHN // Diabetes Care;Dec2011, Vol. 34 Issue 12, p2491 

    OBJECTIVE--Participants in ADVANCE were drawn from many countries. We examined whether the effects of intensive glycemic control on major outcomes in ADVANCE differ between participants from Asia, established market economies (EMEs), and eastern Europe. RESEARCH DESIGN AND METHODS--ADVANCE was a...

  • Risk Factors for Diabetic Peripheral Neuropathy in Subjects with Good Glycaemic Control: the Role of Ankle Brachial Pressure Index. Elliott, Jackie; Rajbhandari, Satyan; Emery, Celia; Ward, John; Tesfaye, Solomon // Diabetes;Jun2007 Supplement 1, Vol. 56, pA80 

    The Diabetes Control and Complications Trial (DCCT) reported a 60% reduction in the development of diabetic peripheral neuropathy (DPN) in the intensively treated cohort, but the incidence of DPN (7-12%) and abnormal nerve conduction (16-33%) remained substantial. Thus DPN can develop despite...

  • CYTRX CLINICAL TRIAL OF ARIMOCLOMOL FOR ALS SHOWS PROMISE.  // Biotech Business;Aug2007, Vol. 20 Issue 8, p6 

    The article reports that biopharmaceutical company CytRx Corp. in Los Angeles, California, has released results from its complete Phase IIa clinical trial with arimoclomol in ALS volunteers. The company observed a decrease in the rate of decline of 21 percent for ALSFRS-R, 8.0 percent for vital...

  • Population-based normative values for the Western Ontario and McMaster (WOMAC®) osteoarthritis index and the Australian/Canadian (AUSCAN) hand osteoarthritis index functional subscales. Bellamy, Nicholas; Wilson, C.; Hendrikz, J. // Inflammopharmacology;Feb2010, Vol. 18 Issue 1, p1 

    To develop age- and gender-specific normative values for the physical function subscales of the WOMAC® and AUSCAN Indices. A scannable survey questionnaire capable of capturing WOMAC® and AUSCAN Index and demographic information was developed, pre-tested, and distributed to a stratified...

  • The Association between Dietary Glycemic Index, Glycemic Load and Children Obesity: A Review of Published Papers. Rouhani, Seyed Mohammad Hossein; Hashemipour, Mahin; Kelishadi, Roya; Esmaillzadeh, Ahmad; Azadbakht, Leila // Journal of Isfahan Medical School;2/13/2012, Vol. 29 Issue 166, p1 

    Background: Many studies were conducted to evaluate the association between dietary glycemic index, glycemic load and children obesity. The aim of this study was to review these studies. Methods: We searched the ISI and PubMed databases for studies that evaluated the association between dietary...

  • Oseltamivir pharmacokinetics in morbid obesity (OPTIMO trial). Thorne-Humphrey, L. M.; Goralski, K. B.; Slayter, K. L.; Hatchette, T. F.; Johnston, B. L.; McNeil, S. A. // Journal of Antimicrobial Chemotherapy (JAC);Sep2011, Vol. 66 Issue 9, p2083 

    Background Detailed pharmacokinetics to guide oseltamivir (Tamiflu®) dosing in morbidly obese patients is lacking. Methods The OPTIMO trial was a single-centre, non-randomized, open-label pharmacokinetic study of single-dose and steady-state oral oseltamivir phosphate and its carboxylate...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics